Fedratinib treatment correlates with suppressed STAT3/AKT/calpain-1 signaling and inhibits hepatocellular carcinoma progression. (PubMed, Transl Gastroenterol Hepatol) - Oct 14, 2026 - "In terms of molecular changes, fedratinib decreased the phosphorylation levels of STAT3 and AKT without affecting total protein expression, reduced calpain-1 expression and enzymatic activity, as well as downregulation of the anti-apoptotic protein Bcl-2. These results demonstrate that fedratinib treatment is associated with reduced STAT3 and AKT phosphorylation, diminished calpain-1 expression and enzymatic activity, and impaired malignant phenotypes in HCC, providing preliminary evidence supporting further evaluation of fedratinib as a candidate therapeutic agent for HCC."
IO biomarker • Journal • Hematological Disorders • Hematological Malignancies • Hepatocellular Cancer • Oncology • Solid Tumor • BCL2 • CAPN1 • STAT3
|
|
Ailifeire Maimaitituerxun; Futian Tang; Junjie Shao; Limei Shuai; Shuangyi Li; Sijing Chen; Ting Liu; Wenjiao Gu; Xiaochun Zhou; Xinghuai Wang; Ying Jiang; Yujie Wei; Yumin Li; Yunqi Pan; Yunyang Zhao; Zhihui Zhao
|